enviornment prescribed drugs, Inc. (ARNA) CEO Amit Munshi on Q2 2018 results – salary name Transcript

arena pharmaceuticals, . NASDAQ:ARNA Q2 2018 earnings convention call August 6, 2018 four:30 PM ET

Executives

Kevin Lind – Chief financial Officer

Amit Munshi – President and Chief govt Officer

Preston Klassen – Chief medical Officer

Analysts

Kennen MacKay – RBC Capital Markets

Martin Auster – credit score Suisse judi online

Jessica Fye – JP Morgan

Joseph Schwartz – Leerink partners

Joel Beatty – Citi

Operator

respectable day, everybody, and welcome to area prescribed drugs’ 2d Quarter 2018 economic results and company replace conference name. This call is being recorded. Operator Instructions

I’ll now flip the name over to Kevin Lind, Chief financial Officer of arena. Please go ahead.

Kevin Lind

decent afternoon, each person, and thank you for joining us today. We hope you had an opportunity to evaluation the news liberate we issued past today saying our 2d quarter 2018 economic outcomes. joining me on contemporary name is Amit Munshi, our President and Chief govt Officer; and Dr. Preston Klassen, our Chief clinical Officer.

before we initiate, i want to remind you that we’ll make ahead-looking statements that contain dangers and uncertainties, together with statements about our focal point, plans, desires, approach, expectations, medical programs, R&D, regulatory actions and operations, and different statements that don’t seem to be ancient data.

These statements are made within the context of the dangers and uncertainties that are discussed in our filings with the U.S. Securities and change commission, which may also be found on the SEC site at .sec.gov, and include hazards concerning the amount and allocation of our purchasable financial and other materials, regulatory decisions and discussions, timing of the initiation of our trials, patient recruitment for our trials, which is competitive and challenging and may steal longer than we venture, statistics related to drugs and drug candidates and the timing of that data, which can also no longer be as anticipated or ample for additional construction, regulatory approval, or commercialization, and collaborative activities. Our precise outcomes may additionally vary materially from our forward-searching statements.

Now, i might like to turn the call over to Amit.

Amit Munshi

Thanks, Kevin. good afternoon, everyone, and thanks for becoming a member of our name. right through my comments today, i will provide the pipeline and company updates as we proceed to increase our promising product building classes. Preston will supply updates to the Ralinepag, section 3 improve program; after which Kevin will provide a economic overview of the 2nd quarter 2018, and we will conclude as ordinary by way of taking questions.

searching ahead, we are expecting a major number of cost riding catalyst over the subsequent one year to 24 months. in the close time period, we’re focused on initiating numerous phase three analyze for ralinepag and the olorinab phase 2 readout in September. additionally, following the interesting data for etrasimod, we’re advancing towards a part three application in Ulcerative Colitis or UC, as smartly as the program in Crohn’s ailment concentrated on quick time-to-market.

 

Leave a Reply

Your email address will not be published. Required fields are marked *